Found: 4
Select item for more details and to access through your institution.
Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2012, v. 67, n. 9, p. 2236, doi. 10.1093/jac/dks175
- By:
- Publication type:
- Article
Molecular and cytogenetic analysis of the spreading of X inactivation in a girl with microcephaly, mild dysmorphic features and t(X;5)(q22.1;q31.1).
- Published in:
- European Journal of Human Genetics, 2008, v. 16, n. 8, p. 897, doi. 10.1038/ejhg.2008.28
- By:
- Publication type:
- Article
Virologic failure in an HIV-infected woman given desogestrel for excessive menstrual bleeding.
- Published in:
- 2011
- By:
- Publication type:
- Case Study
Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.
- Published in:
- Fundamental & Clinical Pharmacology, 2012, v. 26, n. 2, p. 204, doi. 10.1111/j.1472-8206.2010.00905.x
- By:
- Publication type:
- Article